Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelinePrognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelEvaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarraysOptimal systemic therapy for early breast cancer in women: a clinical practice guidelineImmunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
P2860
Q26853619-5BE02048-7BF9-4B0B-8BCD-404DC0518E24Q27853207-0D5FFB6F-6FEF-4ED1-A247-365689E72FE3Q28728830-20E58894-ED02-4B2D-AE83-BEF4D78E36CAQ34466187-52EDC356-4FB6-49E1-BA5A-F8EE85590191Q35239634-7C657205-1E04-472C-B7A6-F75704BB11C8Q35807180-7F82BB4D-5149-4CCC-9FC2-A4B94F31F8D4Q36994974-581EEFBA-F112-4638-97E5-70E132286BA5Q37704344-2A858CB2-33CF-4CD1-B354-AEB3FF3297C5Q42344024-D15D3595-7513-4791-AEDF-65EECF916BF4Q46083625-8BF5E17D-F1DE-4B31-BFC1-E9D5D3B16CB4Q55066764-828A9B70-86BD-4E86-B543-6BEA7FD41ECA
P2860
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@ast
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@en
type
label
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@ast
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@en
prefLabel
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@ast
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@en
P2093
P2860
P50
P356
P1476
Protein expression, survival a ...... NCLCC-PACS 01 randomized trial
@en
P2093
Anne-Laure Martin
Benjamin Esterni
Daniel Birnbaum
Daniel Serin
Fabrice Andre
François Bertucci
Henri Roche
Jean-Marie Boher
Mario Campone
Pascal Finetti
P2860
P2888
P356
10.1186/BCR3051
P577
2011-11-01T00:00:00Z
P5875
P6179
1047184357